Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a 66-cent pill replace CPAP for sleep apnea?

NCT ID NCT05804084

Disease control Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether acetazolamide, a cheap and well-tolerated diuretic, can help people with obstructive sleep apnea who cannot use a CPAP mask. Sixty adults with moderate to severe sleep apnea will receive either the drug or a placebo for 4 weeks each. Researchers will measure sleep apnea severity, memory, and quality of life to see if this pill offers a new treatment option.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2023

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Body mass index ≤ 35 kg/m2 * Untreated moderate/severe OSA (AHI ≥15/h) Exclusion Criteria: * Substantial sleep hypoxemia (SpO2\<80% for \>10% of the monitoring time during the home sleep test, or for \>25% of the total sleep time during any of the in-laboratory studies) * Abnormally low blood counts/electrolytes or renal function at baseline * Use of OSA therapy during the past 1 month, or plans to urgently resume/(re)start clinical OSA therapy within 3 months * Significant, uncontrolled cardiac, pulmonary, endocrine, renal, hepatic, neurocognitive, psychiatric, or urologic (e.g., kidney stones) disorder * Other major sleep disorder (e.g., narcolepsy) * Urgent need to initiate effective OSA therapy (i.e., Epworth sleepiness score \>18, commercial driver, prior sleep-related car accident, or based on MD judgment) * Severe allergy to sulfa-drugs or taking another carbonic-anhydrase inhibitor (e.g., topiramate) * Pregnancy/breastfeeding (current/planned) * Prisoners * Illicit substance abuse or \>2 standard drinks of alcohol/day * Medications that may affect OSA or ventilatory control (e.g., opiates, sedatives) * Thiazide/loop diuretic (risk of hypokalemia) * Inability to give consent or follow procedures * Safety concern based on MD judgment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obstructive sleep apnea are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

obstructive sleep apnea syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obstructive sleep apnea

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • UC San Diego; Altman Clinical and Translational Research Institute Building

    RECRUITING

    La Jolla, California, 92121, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.